Thyroid carcinomas with a variable insular component : Prognostic significance of histopathologic patterns

✍ Scribed by Vittoria Rufini; Massimo Salvatori; Guido Fadda; Luigi Pinnarelli; Paola Castaldi; Maria Lodovica Maussier; Guido Galli

• Publisher: John Wiley and Sons
• Year: 2007
• Tongue: English
• Weight: 413 KB
• Volume: 110
• Category: Article
• ISSN: 0008-543X
• DOI: 10.1002/cncr.22913

✦ Synopsis

Abstract

BACKGROUND.

An insular growth pattern may be observed focally both in papillary and follicular thyroid carcinoma. The aim of the current study was to determine whether a greater extension of the insular component (IC) influences different clinical and histologic features at diagnosis, and a different tumor aggressiveness in terms of frequency in the occurrence of metastases as well as survival.

METHODS.

Thirty‐three patients with histopathologic findings consistent with IC were included in the study. IC was focal (<50% of the tumor area) in 16 patients and predominant (>50% of the tumor area) in 17 patients. These 2 groups were compared with a control group of 66 patients with differentiated thyroid carcinoma.

RESULTS.

At diagnosis, carcinomas with predominant IC differed from those with focal IC with regard to greater tumor size and a higher frequency of extrathyroidal extension and distant metastases. Patient follow‐up ranged from 5 to 188 months. The cumulative rate of distant metastases was significantly higher in patients with predominant IC. At the time of last follow‐up, carcinomas with predominant IC demonstrated a lesser frequency of disease‐free outcome (P = .002) and a higher number of tumor‐related deaths (P = .002), either when distant metastases were present (P = .03) or absent (P = .05) at the time of diagnosis.

CONCLUSIONS.

The presence of predominant IC is associated with a poor prognosis in terms of ongoing disease or death. Predominant IC should be considered a separate entity from not only the classical papillary or follicular carcinomas but also the focal IC tumor. Cancer 2007. © 2007 American Cancer Society.